Introduction
Cervical infections are one of the types of diseases common in primary health-care facilities and pose a serious threat to the health and safety of patients. As a third-generation antibiotic cystasy, it plays an important role in the treatment of abdominal infections, with a wide spectrum of antibacterial activity, long half-lifes and good tissue penetration. However, their rational use is essential to ensure efficacy and to avoid drug resistance.
II. Overview of abdominal infections
(i) Common causes
Cervical infections, which usually result from gastrointestinal perforation, appendixitis, cholesterolitis, vasectomy, fracture of the abdominal post-traumatic organs etc., cause bacteria in the gastrointestinal tract to enter the abdominal cavity and cause inflammatory reactions.
(ii) Pathogen distribution
Patients with abdominal infections are mostly co-infections with grenacin and anaerobic bacteria. Common eclampsia include coli, crebella pneumonia, copper-green characterium, etc., and anaerobic bacteria are mainly vulnerable to fungi. These pathogens are highly pathogenic and resistant, making treatment more difficult.
III. Pharmacological properties of pine hair
(i) Antibacterial spectra
Head spasms have a strong anti-bacterial activity for the gebrane cacteria, with significant inhibitions and extinctions of the grelan crebercus, which are common for the abdominal infections, as well as some anti-bacterial effects for part of the grelane fungi, and some coverage of the anaerobic bacteria, especially when used in conjunction with other anti-aerobic drugs, can be effective for abdominal co-infections.
(ii) Pharmaceutical dynamics
The long half-life of twilight, which can last 6-9 hours and is available once a day, not only facilitates the patient ‘ s access to medication, but also contributes to the patient ‘ s dependence. It has good tissue penetration, has effective fungicide concentrations in abdominal tissues, cholesterol, etc., and is continuously antibacterial and effective in removing pathogenic bacteria from the infected stove.
Drug use programmes
(i) Dose and route of delivery
For abdominal infections in adults, the general dose is 1 – 2 g per day and can be increased to 4 g per day for severe infections, with 1 – 2 intravenous drops. The child dose is based on body weight and is generally 50 – 100 mg/kg per day, divided between 1-2 times. In primary health-care institutions, the dose should be adjusted to take account of the patient ‘ s severity, age, liver and kidney function, among other factors, to ensure that the medication is safe and effective.
(ii) Treatment
The treatment of abdominal infections is usually 7 – 14 days, but the specific treatment should be determined on the basis of the patient ‘ s clinical symptoms, the results of laboratory examinations (e.g. blood routines, C Reacting Protein, calcium calcium reduction indicators, etc. return to normal), as well as visual examinations (e.g. abdominal ultrasound, CT showing abdominal inflammation). For a number of complex abdominal infections, such as a combination of sepsis formation and diabetes, the treatment process may need to be extended appropriately.
V. EFFECT ASSESSMENT
In the treatment of abdominal infections, the patient ‘ s condition is closely observed. Periodically review whether the patient ‘ s temperature, abdominal pain, abdominal swelling, etc. have been reduced, such as abdominal pain, or absconding pain. At the same time, in conjunction with laboratory tests, the dynamics of the indicators of albino-cell count, the ratio of neutral particles and C reaction to inflammation diseases are monitored to assess the effects of treatment. If, after 3 to 5 days of treatment, the patient ‘ s symptoms are not significantly improved or the inflammation indicators continue to rise, consideration should be given to the case of pathogen resistance, the failure of the drug to effectively cover the fungus, and the presence of uninvolved sepsis in the abdominal cavity, and the need to adjust the treatment programme in a timely manner, such as the replacement of antibiotics, further diagnostic measures (e.g. abdominal reinforcement of CT) or surgical interventions (e.g. sepsis).
VI. Adverse effects monitoring
The adverse effects of twilight are relatively small, but still require close attention. Common adverse effects include gastrointestinal reaction, such as nausea, vomiting, diarrhoea, etc.; allergies, such as rashes, itching, measles, etc., can cause allergies in severe cases; a small number of patients may suffer from damage to liver and kidney function, in the form of increased retinase, haematosis, etc.; in addition, there may be abnormal blood system, such as reduction in white cells, reduction in blood panels, etc. In the course of drug use, medical personnel at the primary level should ask for details of the patient ‘ s history of drug allergies, carry out pre-medicine tests, closely observe the patient ‘ s symptoms and signs during the drug, immediately stop the drug if there is a negative reaction, and take appropriate treatments, such as allergies, liver and kidneys, in accordance with the severity of the adverse response, to ensure the patient ‘ s safety.
Joint use
Given that abdominal infections are mostly co-infections, other drugs are often needed to enhance antibacterial effects when using head spines. For patients suspected of anaerobic infections, a combination of nitroglycerin-type drugs, such as americium or americium, can enhance antibacterial activity against anaerobic bacteria. However, in the case of joint use, attention should be paid to the interaction of drugs and the problem of the accumulation of adverse effects. For example, co-use of corrosions with calcium-containing solutions may result in a mirical calcium deposition, leading to a serious adverse reaction, and should therefore be used in such a way as to avoid infusion with calcium-containing preparations on the same dropway.
Conclusions
In primary health-care institutions, the rational use of head spines for the treatment of abdominal infections requires a comprehensive consideration of a wide range of factors, including accurate diagnosis, the development of individualized drug programmes based on the condition, close efficacy assessment and adverse effects monitoring, and a reasonable combination of drugs. Only in this way can the anti-bacterial advantage of hysteria be fully realized, the rate of abdominal infections be improved, the production of drug-resistant bacteria be reduced, the health and medical safety of patients be ensured, and the appropriate use of anti-bacterial drugs in primary health-care institutions be upgraded to contribute to the development of primary health care.
